We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Redx Pharma Plc | LSE:REDX | London | Ordinary Share | GB00BSNB6S51 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 15.00 | 12.00 | 17.00 | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMREDX
RNS Number : 9334S
Redx Pharma plc
14 March 2023
REDX PHARMA PLC
("Redx" or "the Company")
Result of Annual General Meeting
Alderley Park, UK, 14 March 2023 Redx (AIM:REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease announces that its Annual General Meeting was held at 11am on 14 March 2023, with all resolutions passed by substantial majorities.
The table below sets out the details of the votes put to shareholders
Resolution Resolution Number % of votes Number % of % of Total number name of votes for & of votes votes votes votes for & discretionary against against withheld* cast (including discretionary withheld) Receive the Company's 1 annual accounts 306,243,523 94.91% 16,434,331 5.09% 0.00% 322,680,605 ---------------- ---------------- ---------------- ----------- -------- ---------- ---------------- Re-appoint Ernst & Young 2 as auditors 322,677,854 100.00% 2,751 0.00% 0.00% 322,680,605 ---------------- ---------------- ---------------- ----------- -------- ---------- ---------------- Re-elect Dr Bernhard Kirschbaum 3 as a director 306,241,648 94.91% 16,436,206 5.09% 0.00% 322,680,605 ---------------- ---------------- ---------------- ----------- -------- ---------- ---------------- Re-elect Lisa Anson 4 as a director 322,678,730 100.00% 1,875 0.00% 0.00% 322,680,605 ---------------- ---------------- ---------------- ----------- -------- ---------- ---------------- Re-elect Natalie Berner 5 as a director 322,673,730 100.00% 6,875 0.00% 0.00% 322,680,605 ---------------- ---------------- ---------------- ----------- -------- ---------- ---------------- Authorise the directors to allot 6 shares 322,551,347 99.96% 125,732 0.04% 0.00% 322,680,605 ---------------- ---------------- ---------------- ----------- -------- ---------- ---------------- Disapply pre-emption 7 rights 322,545,847 99.96% 133,983 0.04% 0.00% 322,680,605 ---------------- ---------------- ---------------- ----------- -------- ---------- ----------------
*A vote withheld is not a vote in law and is not counted in the calculation of the proportion of votes 'For' or 'Against'
For further information, please contact: Redx Pharma Plc T: +44 (0)1625 469918 UK Headquarters Caitlin Pearson, Head of Communications ir@redxpharma.com Lisa Anson, Chief Executive Officer US Office Peter Collum, Chief Financial Officer SPARK Advisory Partners (Nominated Adviser) T: +44 (0)203 368 3550 Matt Davis/ Adam Dawes WG Partners LLP (Joint Broker) T: +44 (0)203 705 9330 Claes Spång/ Satheesh Nadarajah/ David Wilson Panmure Gordon (UK) Limited (Joint Broker) T: +44 (0)207 886 2500 Rupert Dearden/ Freddy Crossley/ Emma Earl FTI Consulting T: +44 (0)203 727 1000 Simon Conway/ Ciara Martin
About Redx Pharma Plc
Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease and the emerging area of cancer-associated fibrosis, aiming initially to progress them to clinical proof of concept before evaluating options for further development and potential value creation. The Company's lead fibrosis product candidate, the selective ROCK2 inhibitor RXC007, is in development for interstitial lung disease and commenced a Phase 2a trial for idiopathic pulmonary fibrosis (IPF) in October 2022, with topline data expected in Q1 2024. Redx's lead oncology product candidate, the Porcupine inhibitor RXC004, being developed as a targeted treatment for Wnt-ligand dependent cancers, is expected to report both monotherapy and combination with anti-PD-1 Phase 2 data during 2023. Redx's third drug candidate, RXC008, a GI-targeted ROCK inhibitor for the treatment of fibrostenotic Crohn's disease, is progressing towards a CTA/IND application at the end of 2023.
The Company has a strong track record of discovering new drug candidates through its core strengths in medicinal chemistry and translational science, enabling the Company to discover and develop differentiated therapeutics against biologically or clinically validated targets. The Company's accomplishments are evidenced not only by its two wholly-owned clinical-stage product candidates and rapidly expanding pipeline, but also by its strategic transactions, including the sale of pirtobrutinib (RXC005, LOXO-305), a non-covalent (reversible) BTK inhibitor now approved by the US FDA for adult patients with mantle cell lymphoma previously treated with a covalent BTK inhibitor, and AZD5055/RXC006, a Porcupine inhibitor targeting fibrotic diseases including IPF, which AstraZeneca is progressing in a Phase 1 clinical study. In addition, Redx has forged collaborations with Jazz Pharmaceuticals, which includes JZP815, a pan-RAF inhibitor developed by Redx which Jazz is now progressing through Phase 1 clinical studies, and an early stage oncology research collaboration.
To subscribe to Email Alerts from Redx, please visit: www.redxpharma.com/investor-centre/email-alerts/
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
RAGDZGMFMDMGFZM
(END) Dow Jones Newswires
March 14, 2023 07:45 ET (11:45 GMT)
1 Year Redx Pharma Chart |
1 Month Redx Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions